601 related articles for article (PubMed ID: 17926162)
1. Ovarian function and childbearing issues in breast cancer survivors.
Gadducci A; Cosio S; Genazzani AR
Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162
[TBL] [Abstract][Full Text] [Related]
2. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
Tham YL; Sexton K; Weiss H; Elledge R; Friedman LC; Kramer R
Am J Clin Oncol; 2007 Apr; 30(2):126-32. PubMed ID: 17414460
[TBL] [Abstract][Full Text] [Related]
3. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
Reh A; Oktem O; Oktay K
Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
[TBL] [Abstract][Full Text] [Related]
6. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects.
Reichman BS; Green KB
J Natl Cancer Inst Monogr; 1994; (16):125-9. PubMed ID: 7999454
[TBL] [Abstract][Full Text] [Related]
8. Measuring ovarian function in young cancer survivors.
Su HI
Minerva Endocrinol; 2010 Dec; 35(4):259-70. PubMed ID: 21178920
[TBL] [Abstract][Full Text] [Related]
9. Preservation of fertility and the impact of subsequent pregnancy in patients with premenopausal breast cancer.
Park M; Davidson R; Fox K
Semin Oncol; 2006 Dec; 33(6):664-71. PubMed ID: 17145346
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial.
Groenvold M; Fayers PM; Petersen MA; Mouridsen HT
Breast Cancer Res Treat; 2006 Aug; 98(3):275-84. PubMed ID: 16541325
[TBL] [Abstract][Full Text] [Related]
11. Fertility options in young breast cancer survivors: a review of the literature.
Dow KH; Kuhn D
Oncol Nurs Forum; 2004 May; 31(3):E46-53. PubMed ID: 15152274
[TBL] [Abstract][Full Text] [Related]
12. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
[TBL] [Abstract][Full Text] [Related]
13. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
[TBL] [Abstract][Full Text] [Related]
14. Fertility and adjuvant treatment in young women with breast cancer.
Partridge AH; Ruddy KJ
Breast; 2007 Dec; 16 Suppl 2():S175-81. PubMed ID: 17804236
[TBL] [Abstract][Full Text] [Related]
15. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors.
Knobf MT
Oncologist; 2006 Feb; 11(2):96-110. PubMed ID: 16476831
[TBL] [Abstract][Full Text] [Related]
16. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
Hahn KM; Johnson PH; Gordon N; Kuerer H; Middleton L; Ramirez M; Yang W; Perkins G; Hortobagyi GN; Theriault RL
Cancer; 2006 Sep; 107(6):1219-26. PubMed ID: 16894524
[TBL] [Abstract][Full Text] [Related]
18. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
Partridge A; Gelber S; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Winer E
Eur J Cancer; 2007 Jul; 43(11):1646-53. PubMed ID: 17512721
[TBL] [Abstract][Full Text] [Related]
19. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
Yasumura T; Oka T; Honjo H; Okada H
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733
[TBL] [Abstract][Full Text] [Related]
20. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.
Petrek JA; Naughton MJ; Case LD; Paskett ED; Naftalis EZ; Singletary SE; Sukumvanich P
J Clin Oncol; 2006 Mar; 24(7):1045-51. PubMed ID: 16476708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
